NATHAN RILEY: Open Payments
NPI 1316182934 · EVANSVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,583 in 92 payments from 20 companies in 2025. Trend: 2023 $726 · 2024 $1,178 · 2025 $1,583
Food & beverage: $1,583
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $513 |
| Axsome Therapeutics, Inc. | 11 | $148 |
| AstraZeneca Pharmaceuticals LP | 6 | $140 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $129 |
| Sumitomo Pharma America, Inc. | 4 | $68 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $63 |
| Novo Nordisk Inc | 4 | $61 |
| Lilly USA, LLC | 3 | $60 |
| Exact Sciences Corporation | 4 | $60 |
| Phathom Pharmaceuticals, Inc. | 3 | $47 |
Products named: QULIPTA, VRAYLAR, Auvelity, UBRELVY, CAPLYTA, FARXIGA, Kerendia, REXULTI.
Industry payments across IN — which companies pay providers there.
